Natural history & clinical outcomes in adults with NAFLD
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic fatty liver disease (NAFLD) with lessons from cohort studies and placebo arms of trials. The take home points are that the natural history of NAFLD is variable
Video Natural history & clinical outcomes in adults with NAFLD -Copyright ©2022 by PanNash™ Initiative - All rights reserved.
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic fatty liver disease (NAFLD) with lessons from cohort studies and placebo arms of trials. The take home points are that the natural history of NAFLD is variable. Further, the placebo response varies according to trial length, regression to mean as well as sample size. Advanced fibrosis (F3/F4) drives clinical outcomes in non-alcoholic steatohepatitis (NASH) with very high hazard ratios in decompensation and mortality in patients with F4 Fibrosis compared to those with earlier stages of fibrosis.
- Dr. Kris Kowdley
- September 27, 2022
- More Pathophysiology, Risks (Morbi-mortality)
Would you like to read more?
Dr. Kris Kowdley
Exploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and…
NAFLD and Cardiovascular Diseases: What is The Link?
Recent research into non-alcoholic fatty liver disease (NAFLD) has noted its distinct association with cardiovascular diseases (CVDs).
Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through…
Insights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?
The growing global prevalence of metabolic diseases, e.g. hypertension, type 2 diabetes mellitus (T2DM), hyperlipidaemia, obesity, and non-alcoholic fatty liver…
NIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2)…
Are Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus…
Exploring the Potential Link Between COVID-19 and the Surge in Pediatric NAFLD
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease in children, has seen a consistent rise in prevalence in…
"Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been…
Understanding Nash: Symptoms, Detection, And Treatment
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in…
PPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and…
Ballooning Hepatocytes In Nash: Mechanisms, Implications, And Technological Advances
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated…
An exploration of MAFLD’s clinical utility
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty…
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
